8-K: Neogen Reports Q3 FY26 Results, Divests Genomics Unit

Neogen Corporation announced third quarter fiscal year 2026 financial results, reporting a revenue decrease of 4.4% to $211.2 million, while also revealing the divestiture of its Genomics business for $160 million.

Summary

• Neogen Corporation reported third quarter fiscal year 2026 revenue of $211.2 million, a 4.4% decrease compared to the prior year's $221.0 million.
• Food Safety segment revenue increased by 2.6% to $156.7 million, with core Food Safety revenue up 4.0%.
• Animal Safety segment revenue decreased by 20.1% to $54.5 million, impacted by third-party supplier challenges, with core Animal Safety revenue down 8.7%.
• The company reported a net loss of $17.0 million, or $(0.08) per diluted share, compared to a net loss of $10.9 million, or $(0.05) per diluted share, in the prior year.
• Adjusted Net Income was $19.4 million, or $0.09 per diluted share, down from $20.9 million, or $0.10 per diluted share, in the prior year.
• Adjusted EBITDA was $48.2 million, with an Adjusted EBITDA Margin of 22.8%, an increase from 22.0% in the prior year.
• Neogen announced the divestiture of its Genomics business to Zoetis Inc. for $160 million, expected to close in the second quarter of fiscal year 2027.
• The company is increasing its fiscal year 2026 revenue guidance to $857-$860 million and maintaining its Adjusted EBITDA guidance of approximately $175 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report with positive strategic moves but ongoing operational challenges impacting revenue and profitability.

Positives

• Food Safety segment revenue grew 2.6% to $156.7 million, with core growth of 4.0%.
• Indicator Testing & Culture Media revenue increased 11.0%, and Bacterial & General Sanitation revenue increased 5.5%.
• Adjusted EBITDA margin increased to 22.8% from 22.0% in the prior year, driven by cost-saving initiatives.
• The Petrifilm manufacturing transition is on track for completion by November 2026.
• Fiscal year 2026 revenue outlook has been raised to $857-$860 million.
• The divestiture of the Genomics business is expected to generate net cash proceeds of approximately $140 million.
• The company aims to achieve a net debt-to-adjusted EBITDA ratio of less than three times by the end of CY2026.

Negatives

• Total revenue decreased by 4.4% to $211.2 million.
• Animal Safety segment revenue declined 20.1% to $54.5 million, primarily due to third-party supplier issues.
• Core Animal Safety revenue decreased by 8.7%.
• Net loss for the quarter was $17.0 million, compared to a net loss of $10.9 million in the prior year.
• Adjusted Net Income decreased to $19.4 million from $20.9 million in the prior year.
• Gross margin decreased to 46.9% from 49.9% due to duplicative costs from the Petrifilm manufacturing transition and other factors.
• Biosecurity Products revenue in Food Safety decreased by 66.9% and in Animal Safety by 37.0%.

Risks

• Third-party supplier challenges significantly impacted Animal Safety segment revenue.
• The Petrifilm manufacturing transition involves duplicative costs and operational complexities.
• Risks associated with the integration of the 3M Food Safety business.
• Potential disruptions in manufacturing and service operations.
• Dependence on key suppliers and distributors.
• Increased raw material costs.
• Competition within the food safety and animal health markets.
• The company has substantial indebtedness.

Future Outlook

Neogen is increasing its fiscal year 2026 revenue guidance to $857-$860 million and maintaining its Adjusted EBITDA guidance of approximately $175 million. The company anticipates the divestiture of its Genomics business to close by the second quarter of fiscal year 2027.

Management Comments

• "We continued to make significant progress on our strategic transformation in the third quarter as we look to stabilize and strengthen our core business. We are emboldened by the continued strength in core growth in our Food Safety segment."
• "In the third quarter our Animal Safety business suffered several third-party, supply-based, setbacks leading to lower-than-anticipated growth, and we are actively engaged in improving these production-related challenges through our supplier qualification and sales and operations planning process."
• "Despite these transient issues, we were able to deliver strong adjusted EBITDA through solid cost control and we continue to see opportunities to drive efficiency through technology and process across the company."
• "We are confident that we will emerge from this fiscal year stronger and more capable as an organization, and increasingly focused on building upon our market leading position in Food Safety through discipline, improved enterprise capabilities, a renewed focus on innovation leadership, and a dramatically improved selling process."

Industry Context

StockSavvy.ai notes that Neogen's results reflect a common challenge in the life sciences and diagnostics sector: supply chain disruptions impacting specific segments while others show resilience. The strategic divestiture of the Genomics unit signals a focus on core competencies, a trend observed across the industry as companies streamline operations.

Stakeholder Impact

• Shareholders: The divestiture of the Genomics business and increased revenue guidance may be viewed positively, while the net loss and revenue decline in Animal Safety present concerns.
• Employees: Strategic transformation and potential realignment of resources could impact workforce dynamics.
• Suppliers: The company is actively working to improve relationships and address challenges with third-party suppliers in the Animal Safety segment.
• Creditors: The company's stated goal to reduce net debt-to-adjusted EBITDA to below three times by end of CY2026 is a positive indicator for creditors.

Next Steps

• Complete the transition of the Petrifilm manufacturing line by November 2026.
• Close the divestiture of the Genomics business by the second quarter of fiscal year 2027.
• Continue to implement strategic sales initiatives and metric-based performance analysis.
• Address and improve production-related challenges within the Animal Safety segment through supplier qualification and sales and operations planning.

Key Dates

Recommendation

The company is navigating significant operational challenges, particularly in its Animal Safety segment, while making strategic progress with the divestiture of its Genomics business and improvements in its Food Safety segment. The increased revenue guidance is positive, but the net loss and ongoing supply chain issues warrant a cautious 'hold' stance until sustained improvement is demonstrated.

Keywords

Neogen Corporation, 8-K, Financial Results, Food Safety, Animal Safety, Genomics Business, Divestiture, Revenue